PRAX News and Press, Praxis Precision Medicines Inc. From 12/29/25

2025-12-29 09:29:05 ET More on Praxis Precision Medicines Praxis Precision Medicines: Latest Study Wins Sets Up 2 CNS Drug Approvals In 2026 Praxis: Moving To Strong Buy Based On Ulixacaltamide Success In Treating ET Praxis Precision Medicines, Inc. (PRAX) Discusses ...

The Breakthrough Therapy Designation was granted based on the positive topline results from the Essential3 Phase 3 program in essential tremor Praxis remains on track to submit ulixacaltamide NDA in early 2026 based on recently completed pre-NDA meeting with the FDA BOSTON, Dec. 29, 2025 (...

2025-12-29 06:15:02 ET BTIG analyst issues BUY recommendation for PRAX on December 29, 2025 11:14AM ET. The previous analyst recommendation was Buy. PRAX was trading at $268.95 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...

2025-12-22 16:07:25 ET More on healthcare stocks My S&P 500 Prediction On Sector Outperformers And Laggards In 2026 Abivax: "Strong Buy" On Obefazimod New UC Data And Maintenance Results Coming Q2 2026 IHI: A Passive ETF For Medical Device Exposure PACS G...

2025-12-17 12:29:56 ET Fast Facts About the Direxion Daily S&P Biotech Bull 3X ETF Read the full article on Seeking Alpha For further details see: LABU: The Risks And Rewards Of A Leveraged Biotechnology ETF

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 1.5% to $3.34 on volume of 445,890,901 shares WORK Medical Technology Group LTD (WOK) fell 40.0% to $0.0648 on volume of 324,557,228 shares 3 E Network Technology Group Ltd (MASK) ...

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 0.0% to $3.29 on volume of 381,943,310 shares WORK Medical Technology Group LTD (WOK) fell 38.3% to $0.0666 on volume of 269,738,667 shares 3 E Network Technology Group Ltd (MASK) ...

BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition ...

2025-12-09 21:51:49 ET More on Praxis Precision Medicines Praxis Precision Medicines: Latest Study Wins Sets Up 2 CNS Drug Approvals In 2026 Praxis: Moving To Strong Buy Based On Ulixacaltamide Success In Treating ET Praxis Precision Medicines, Inc. (PRAX) Discusses ...

Clear recognition of high unmet need and urgency for the SCN2A community and plausibility of the mechanism of elsunersen FDA agreed to proposed changes to the EMBRAVE3 trial design to be a single-arm, baseline-controlled study Enrollment in EMBRAVE3 is quickly accelerating and...